Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Pfizer Inc.
Moderna, Inc. Common Stock
ABBVIE INC.
AstraZeneca PLC
Merck & Co., Inc.
Eli Lilly & Co.
Procter & Gamble Company
Exxon Mobil Corporation
Novavax Inc
BERKSHIRE HATHAWAY Class B
The chart shows the growth of an initial investment of $10,000 in Johnson & Johnson, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Johnson & Johnson (JNJ) has returned 17.51% so far this year and 60.66% over the past 12 months. Looking at the last ten years, JNJ has achieved an annualized return of 8.37%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Johnson & Johnson (JNJ) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.88% | 8.81% | -1.91% | -1.04% | ||||||||
| 2025 | 4.76% | 8.57% | 0.53% | -2.75% | 0.14% | -1.12% | 7.67% | 7.07% | 4.48% | 1.54% | 9.48% | 0.22% |
| 2024 | 1.26% | 2.04% | -2.25% | -8.32% | -1.39% | -0.74% | 8.06% | 4.66% | -1.92% | -1.58% | -3.47% | -6.55% |
| 2023 | -7.23% | -5.97% | 1.30% | 5.65% | -5.22% | 7.10% | 1.94% | -2.82% | -3.51% | -4.56% | 3.67% | 0.19% |
| 2022 | 1.22% | -4.17% | 8.70% | 1.93% | -0.52% | -0.92% | -1.65% | -7.37% | 1.16% | 5.89% | 2.26% | -1.31% |
| 2021 | 3.75% | -4.14% | 1.80% | 0.08% | 3.45% | -3.18% | 4.53% | 0.38% | -6.59% | 0.84% | -4.43% | 9.05% |
| 2020 | 2.06% | -10.00% | -2.71% | 17.49% | -0.58% | -4.52% | 3.60% | 4.80% | -3.24% | -8.17% | 4.10% | 7.58% |
| 2019 | 3.86% | 1.95% | 1.87% | 0.86% | -6.95% | 5.92% | -7.12% | -1.46% | 1.09% | 1.55% | 4.12% | 5.92% |
| 2018 | -1.05% | -5.56% | -0.74% | -1.04% | -5.30% | 0.80% | 9.21% | 1.74% | 2.58% | 1.25% | 4.88% | -11.35% |
| 2017 | -2.19% | 8.65% | 1.68% | -1.01% | 3.93% | 3.09% | -0.05% | -0.60% | -1.95% | 7.11% | -0.36% | 0.11% |
| 2016 | 3.78% | 0.42% | 7.76% | 3.04% | -4.76% | -0.89% | -1.70% | -3.01% | 3.46% |
The charts below present risk-adjusted performance metrics for Johnson & Johnson (JNJ) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of JNJ compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Johnson & Johnson volatility is 0.94%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 199.21B | 180.10B | 167.56B | 182.02B | 174.89B | 157.73B | 152.95B | 157.30B | 133.41B | 131.12B | 132.68B | 113.64B | 102.91B | 94.68B |
| Equity Attributable To Parent (USD) | 81.54B | 71.49B | 68.77B | 74.02B | 63.28B | 59.47B | 59.75B | 60.16B | 71.15B | 69.75B | 74.05B | 57.08B | 56.58B | 50.59B |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 81.54B | 71.49B | 68.77B | 74.02B | 63.28B | 59.47B | 59.75B | 60.16B | 71.15B | 69.75B | 74.05B | 57.08B | 56.58B | 50.59B |
| Other Non-current Liabilities (USD) | 22.10B | 25.89B | 25.15B | 30.65B | - | - | - | - | - | - | - | - | 14.09B | - |
| Long-term Debt (USD) | 41.44B | 32.40B | 27.35B | 32.12B | - | - | - | - | - | - | - | - | 9.17B | - |
| Noncurrent Liabilities (USD) | 63.54B | 58.29B | 52.50B | 62.77B | 69.12B | 62.29B | 61.97B | 66.61B | 34.51B | 36.28B | 32.96B | 33.75B | 23.26B | 22.36B |
| Other Current Liabilities (USD) | 37.60B | 35.88B | 32.66B | 30.59B | 29.50B | 24.07B | 20.60B | 20.27B | 18.61B | 14.70B | 16.62B | 14.76B | 14.81B | 14.58B |
| Wages (USD) | 4.53B | 4.13B | 3.99B | 3.59B | 3.48B | 3.35B | 3.10B | 2.95B | 2.47B | 2.75B | 2.79B | 2.33B | 2.64B | 1.61B |
| Accounts Payable (USD) | 11.99B | 10.31B | 9.63B | 11.06B | 9.51B | 8.54B | 7.54B | 7.31B | 6.67B | 7.63B | 6.27B | 5.73B | 5.62B | 5.54B |
| Current Liabilities (USD) | 54.13B | 50.32B | 46.28B | 45.23B | 42.49B | 35.96B | 31.23B | 30.54B | 27.75B | 25.09B | 25.68B | 22.81B | 23.07B | 21.73B |
| Liabilities (USD) | 117.67B | 108.61B | 98.78B | 108.00B | 111.62B | 98.26B | 93.20B | 97.14B | 62.26B | 61.37B | 58.63B | 56.56B | 46.33B | 44.09B |
| Other Non-current Assets (USD) | 70.01B | 66.08B | 59.99B | 55.69B | 51.49B | 47.15B | 42.28B | 43.98B | 31.53B | 28.46B | 31.62B | 26.45B | 24.33B | 24.06B |
| Intangible Assets (USD) | 50.40B | 37.62B | 34.18B | 46.39B | 53.40B | 47.64B | 47.61B | 53.23B | 25.76B | 27.22B | 27.95B | 18.14B | 16.72B | 16.32B |
| Fixed Assets (USD) | 23.17B | 20.52B | 19.90B | 18.96B | 18.77B | 17.66B | 17.04B | 17.01B | 15.91B | 16.13B | 16.71B | 14.74B | 14.55B | 14.76B |
| Noncurrent Assets (USD) | 143.59B | 124.21B | 114.06B | 121.04B | 123.66B | 112.45B | 106.92B | 114.22B | 73.20B | 71.81B | 76.28B | 48.27B | 55.60B | 55.14B |
| Other Current Assets (USD) | 41.43B | 43.45B | 42.31B | 50.59B | 41.89B | 36.25B | 37.43B | 34.32B | 52.16B | 18.04B | 19.32B | 15.77B | 41.93B | 34.36B |
| Inventory (USD) | 14.19B | 12.44B | 11.18B | 10.39B | 9.34B | 9.02B | 8.60B | 8.77B | 8.05B | 8.18B | 7.88B | 6.29B | 5.38B | 5.18B |
| Cash (USD) | - | - | - | - | - | - | - | - | - | 33.09B | 29.21B | 32.26B | - | - |
| Current Assets (USD) | 55.62B | 55.89B | 53.50B | 60.98B | 51.24B | 45.27B | 46.03B | 43.09B | 60.21B | 59.31B | 56.41B | 54.32B | 47.31B | 39.54B |
| Assets (USD) | 199.21B | 180.10B | 167.56B | 182.02B | 174.89B | 157.73B | 152.95B | 157.30B | 133.41B | 131.12B | 132.68B | 113.64B | 102.91B | 94.68B |
The article compares two high-yield covered call ETFs: JEPI (low-volatility S&P 500 stocks) and JEPQ (Nasdaq-100 stocks). Given current macroeconomic challenges including slowing GDP growth, negative payroll trends, and inflation concerns, JEPI is recommended as the better choice due to its defensive stock portfolio, while JEPQ's tech-heavy exposure faces headwinds from valuation concerns and economic slowdown.
Johnson & Johnson demonstrates resilience during market downturns, with shares falling less than 2% while the S&P 500 dropped over 7%. The healthcare giant maintains strong fundamentals including 63 consecutive years of dividend increases, $94.2 billion in 2025 revenue (up 6%), and 51 drug approvals last year. However, the stock faces headwinds from tens of thousands of talc-related lawsuits and Medicare drug price negotiations under the Inflation Reduction Act.
The Trump administration is preparing to announce 100% tariffs on pharmaceutical companies that haven't secured pricing deals with the White House, potentially as soon as Thursday. The tariffs stem from a Section 232 investigation citing national security grounds. Major drugmakers including Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and Johnson & Johnson have already secured three-year reprieves by agreeing to most-favored-nation pricing. The tariff threat is part of a broader pricing strategy that includes the TrumpRx.gov platform for comparing discounted drug prices.
Over 120 pharmaceutical companies are actively developing 140+ pipeline drugs for systemic lupus erythematosus (SLE), with approximately 30+ drugs in mid-stage development and 85+ in early stages. Key players include Roche, Biogen, Novartis, AbbVie, and Johnson & Johnson, with promising therapies targeting various mechanisms such as B cell inhibitors, JAK inhibitors, and TLR antagonists. Recent regulatory milestones include FDA Fast Track designation for nipocalimab and Breakthrough Therapy Designation for litifilimab.
Johnson & Johnson is highlighted as a standout Dividend King with 63 consecutive years of dividend increases. The healthcare company's strong pharmaceutical portfolio, diversified medical device business, projected $100 billion in sales, robust pipeline, and AAA credit rating position it well to maintain dividend growth despite economic challenges and government price negotiations.
Johnson & Johnson announced new real-world data from the ECHO study demonstrating that SPRAVATO® (esketamine nasal spray) is effective for treatment-resistant depression with durable effects lasting 6 months after treatment discontinuation. The study of 570 European patients showed significant symptom improvements measured by MADRS scores and a consistent safety profile, with the most common adverse events being dissociation, dizziness, and increased blood pressure.
Intuitive Surgical faces near-term headwinds from tariffs and increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson. Despite trading at a premium valuation of 47.6x forward earnings, the company's strong competitive moat, expanding market opportunity, and consistent financial growth position it as an attractive long-term investment for buy-and-hold investors willing to tolerate near-term volatility.
Elon Musk announced Terafab, a $25 billion joint venture between Tesla, SpaceX, and XAI to build a vertically integrated semiconductor factory producing 1 terawatt of AI computing power annually. The facility aims to address supply chain bottlenecks and support Tesla's robotaxi and humanoid robot ambitions, plus SpaceX's orbital AI satellite constellation. While ambitious, industry experts question feasibility given the complexity of chip fabrication and Musk's mixed track record on delivery timelines.
The article recommends a balanced investment strategy combining offensive and defensive stocks to navigate market uncertainty in Q2 2026. It highlights Johnson & Johnson, NextEra Energy, and Microsoft as stocks that offer both growth potential and defensive characteristics, with strong dividend histories and competitive advantages in their respective sectors.
Nanobiotix (NASDAQ: NBTX) denied media reports of a potential acquisition by Johnson & Johnson, clarifying that no takeover process is underway. The company reaffirmed its focus on advancing its cancer treatment pipeline, particularly its partnership with J&J for the radioenhancer NBTXR3. Shares rose 6.17% to $31.07 following the clarification, with the stock up 774.83% over the past 12 months.